Advisor Group’s Loncar China BioPharma ETF CHNA Stock Holding History

Advisor Group’s Portfolio CHNA Stock Details CHNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$12K	Hold	500	–	–	﹤0.01%	4265
2019 Q3	$11K	Buy	+500	New	+$11.2K	﹤0.01%	4305

Other funds holding CHNA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Advisor Group's CHNA Position: Q4 2019 in Review

Advisor Group held its Loncar China BioPharma ETF (CHNA) position steady in Q4 2019 at 500 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #4265.

Advisor Group first reported a position in CHNA in Q3 2019 and has held it in 2 quarters since. 4 funds tracked by Wall St. Rank hold CHNA as of Q4 2019.

Advisor Group held 500 shares of Loncar China BioPharma ETF worth $12K as of Q4 2019.
Advisor Group left its Loncar China BioPharma ETF share count unchanged in Q4 2019.
Loncar China BioPharma ETF made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4265 holding.
Advisor Group first reported a position in Loncar China BioPharma ETF in Q3 2019 and has held it in 2 quarters since.
4 funds tracked by Wall St. Rank held Loncar China BioPharma ETF as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.